[go: up one dir, main page]

AR097909A1 - Método para determinar el pronóstico del cáncer de páncreas - Google Patents

Método para determinar el pronóstico del cáncer de páncreas

Info

Publication number
AR097909A1
AR097909A1 ARP140103688A ARP140103688A AR097909A1 AR 097909 A1 AR097909 A1 AR 097909A1 AR P140103688 A ARP140103688 A AR P140103688A AR P140103688 A ARP140103688 A AR P140103688A AR 097909 A1 AR097909 A1 AR 097909A1
Authority
AR
Argentina
Prior art keywords
cancer
patient
pancreatic cancer
forecast
determining
Prior art date
Application number
ARP140103688A
Other languages
English (en)
Inventor
Piquemal David
Moussy Alain
Pierre Kinet Jean
Original Assignee
Ab Science
Acobiom
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ab Science, Acobiom filed Critical Ab Science
Publication of AR097909A1 publication Critical patent/AR097909A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Método in vitro para determinar el pronóstico del cáncer de páncreas en un paciente. Más particularmente, este método comprende las siguientes etapas: a) medir el nivel de expresión de al menos un gen seleccionado entre el grupo compuesto por ACOX-1, TNFRSF10B, LYN, HIF1A, UBE2H, PARP2, ABCC1, ABCC3, IGJ y RPS23 o genes homólogos, en una muestra de sangre de dicho paciente; b) predecir el desenlace clínico del cáncer de páncreas en dicho paciente. También se refiere a un kit especialmente diseñado para llevar a cabo dicho método. Reivindicación 19: El uso de al menos un gen seleccionado entre el grupo que comprende ACOX-1, TNFRSF10B, LYN, HIF1A, UBE2H, PARP2, ABCC1, ABCC3, IGJ y RPS23 para el pronóstico del cáncer de páncreas en un paciente.
ARP140103688A 2013-10-04 2014-10-03 Método para determinar el pronóstico del cáncer de páncreas AR097909A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13306381 2013-10-04

Publications (1)

Publication Number Publication Date
AR097909A1 true AR097909A1 (es) 2016-04-20

Family

ID=49448075

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140103688A AR097909A1 (es) 2013-10-04 2014-10-03 Método para determinar el pronóstico del cáncer de páncreas

Country Status (5)

Country Link
US (1) US20160244845A1 (es)
EP (1) EP3052103A1 (es)
AR (1) AR097909A1 (es)
TW (1) TW201514311A (es)
WO (1) WO2015049377A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3025028A1 (fr) * 2014-08-22 2016-02-26 Acobiom Procede pour determiner le pronostic de survie d'un patient atteint d'un cancer du pancreas
MX2017013980A (es) * 2015-05-01 2018-06-15 United Animal Health Inc Metodo y composiciones de deteccion y cuantificacion de acido nucleico.
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
WO2022207566A1 (en) * 2021-03-29 2022-10-06 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to evaluate pancreatic cancer prognosis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120264639A1 (en) * 2009-11-04 2012-10-18 Jen Jen Yeh Methods and compositions for predicting survival in subjects with cancer
US20120309706A1 (en) * 2010-02-01 2012-12-06 Ab Science Combined treatment of pancreatic cancer with gemcitabine and masitinib
EP2716767A1 (en) * 2012-10-04 2014-04-09 Skuldtech Method for determining the prognosis of pancreatic cancer
EA037368B1 (ru) * 2012-10-04 2021-03-19 Аб Сьянс Способ лечения рака поджелудочной железы у пациента, страдающего от связанной с болезнью интенсивной боли, и применение набора, содержащего маситиниб или его фармацевтически приемлемую соль и гемцитаниб, для лечения рака поджелудочной железы

Also Published As

Publication number Publication date
EP3052103A1 (en) 2016-08-10
TW201514311A (zh) 2015-04-16
WO2015049377A1 (en) 2015-04-09
US20160244845A1 (en) 2016-08-25

Similar Documents

Publication Publication Date Title
MX2015011362A (es) Metodo para el pronostico y tratamiento de metastasis de cancer.
MX2017008421A (es) Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga.
DOP2017000094A (es) Composiciones y métodos para inhibir la expresión del gen hao1 (hidroxiácido-oxidasa 1 (glicolato-oxidasa))
MX2017014736A (es) Metodos terapeuticos y diagnosticos para cancer.
WO2013153458A3 (en) Method for the prognosis and treatment of cancer metastasis
BR112014018970A8 (pt) Dispositivos de coleta de amostra com agentes de estabilização sanguínea
MX2016003245A (es) Calreticulina mutante para la diagnosis de malignidades mieloides.
MX2015004610A (es) Metodo para diagnostico, pronostico y tratamiento de metastasis de cancer de prostata usando c-maf.
BR112013004750A2 (pt) derivados de quinolina e quinoxalina como inibidores da cinase
MX2013014153A (es) Biomarcadores paa terapia de inhibidor de hedgehog.
MX2021013938A (es) Metodos y composiciones para prediccion de eficacia terapeutica de tratamientos contra el cancer y prognosis del cancer.
BR112017024091A2 (pt) métodos para o armazenamento de sangue total e composições do mesmo
BR112016007864A2 (pt) método para a prognose e tratamento de metástase de câncer
EP3495502A3 (en) Biomarkers for premature birth
AR097909A1 (es) Método para determinar el pronóstico del cáncer de páncreas
WO2014184679A3 (en) Method for the prognosis and treatment of renal cell carcinoma metastasis
BR112013002738A2 (pt) métodos e compostos para o diagnóstico e o tratamento do câncer
AU2013252445A8 (en) Assays, methods and apparatus for assessing RNA disruption
ES2530743T3 (es) Método in vitro y kit para el pronóstico o predicción de la respuesta por parte de pacientes con artritis reumatoide al tratamiento con agentes bloqueantes del factor TNFalfa
CL2012002347A1 (es) Metodo in vitro para el diagnostico de la demencia con cuerpos de lewy (lbd), que comprende determinar en una muestra biológica de un individuo el genotipo de las siguientes alteraciones en el gen de la butirilcolinesterasa o de polimorfismos en desequilibrio de union de los mismos; kit para llevar a cabo dicho método; uso del kit para el diagnóstico de lbd.
ES2586116T3 (es) Procedimiento y composición para el tratamiento, la prevención y el diagnóstico de cáncer que contiene células madre de cáncer o derivados de las mismas
MX2015002749A (es) Metodo diagnostico y terapeutico para el cancer dirigido a moleculas expresadas en celulas madre cancerosas.
MX2015001788A (es) Metabolitos de metionina predicen la evolución agresiva del cáncer.
WO2014020444A3 (en) Methods and compositions for diagnosis and prognosis in breast cancer
MXPA06014175A (es) Diagnostico o pronostico del curso del cancer de mama.

Legal Events

Date Code Title Description
FB Suspension of granting procedure